Last reviewed · How we verify
Tafamidis 61 mg free acid capsule (Reference) (tafamidis-61-mg-free-acid-capsule-reference)
Tafamidis stabilizes transthyretin, preventing amyloid formation and deposition in tissues.
Tafamidis 61 mg free acid capsule is a transthyretin (TTR) stabilizer developed by Pfizer for treating transthyretin amyloidosis, a rare progressive neurodegenerative disease. The drug works by binding to and stabilizing the TTR protein, preventing its misfolding and aggregation into amyloid fibrils that damage nerves and organs. This formulation represents a Phase 1 development candidate being evaluated for bioavailability and pharmacokinetic properties compared to alternative formulations. The reference free acid capsule is part of Pfizer's formulation optimization strategy to improve drug delivery and patient tolerability. Tafamidis has established commercial significance in the rare disease space, with the approved meglumine salt formulation (Vyndaqel) generating substantial revenue. This free acid capsule development reflects ongoing efforts to optimize the therapeutic profile and potentially expand market access in transthyretin amyloidosis.
At a glance
| Generic name | tafamidis-61-mg-free-acid-capsule-reference |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Mechanism of action
Tafamidis works by binding to and stabilizing the transthyretin protein, which prevents it from misfolding and forming harmful amyloid deposits in the heart and nerves.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: